PIK3CA and neoplasm: To investigate the potential utility of PET scanning as an early surrogate biomarker of tumour response to PI3K and/or MEK inhibitor therapy, PET scanning has been incorporated into efficacy studies in a small number of pre-clinical and clinical studies.